The results of our study show that the novel compound, VKNG-1, significantly reverses MDR in S1-M1-80 cancer cells by blocking the efflux activity of the ABCG2 transporter and downregulating ABCG2 and p-AKT protein. This evidence concerns the gene ABCG2 and cancer.